Le Lézard
Classified in: Health, Business
Subjects: TNM, ACC

dsm-firmenich completes voluntary cash offer for DSM shares


KAISERAUGST, Switzerland and HEERLEN, Netherlands, Feb. 12, 2024 /PRNewswire/ -- DSM-Firmenich AG (the Company or dsm-firmenich) and DSM B.V. (DSM) today announce that the Voluntary Tender Offer for the remaining DSM ordinary shares (previously Koninklijke DSM N.V. with ISIN: NL0000009827, the Shares) as announced on January 8, 2024 (the Voluntary Tender Offer) has been completed.

dsm-firmenich logo

4,163,287 Shares, representing approximately 2.4% of the Shares, have been tendered to the Company under the Voluntary Tender Offer. As a result, the Company now holds approximately 98.5% of the Shares.

The holders of Shares who have sold their Shares through the Voluntary Tender Offer, will receive the offer price of ?96.00 per Share on February 13, 2024, free from withholding or dividend tax. The total consideration payable by the Company under the Voluntary Tender Offer amounts to EUR 399,675,552.

The Company will seek to acquire the remaining approximately 1.5% Shares through the statutory buy-out procedure (the Buy-Out) at the Enterprise Chamber of the Amsterdam Court of Appeal (Ondernemingskamer), which started on July 17, 2023.

Additional information on the Buy-Out can be found on the Company's website (https://www.dsm-firmenich.com).

For more information, please contact:

dsm-firmenich investor relations enquiries:
Email: [email protected]

dsm-firmenich media enquiries:
Email: [email protected]   

About dsm-firmenich
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world's growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss-Dutch company, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than ?12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to lifetm every day, everywhere, for billions of people. www.dsm-firmenich.com 

General restrictions
The Voluntary Tender Offer in jurisdictions other than the Netherlands and Switzerland may be restricted and/or prohibited by law. The Voluntary Tender Offer has not been made, and the Shares have not been accepted for purchase from or on behalf of any holder of the Shares, in any jurisdiction in which the making of the Voluntary Tender Offer or acceptance thereof would not be in compliance with the securities or other laws or regulations of such jurisdiction or would require any registration, approval or filing with any regulatory authority. Outside of the Netherlands and Switzerland, no actions have been taken (nor will actions be taken) to make the Voluntary Tender Offer possible in any jurisdiction where such actions would be required. Neither dsm-firmenich, nor DSM, nor ABN AMRO Bank N.V. accepts any liability for any violation by any person of any such restriction. Any failure to comply with any such restrictions may constitute a violation of the law of any such jurisdiction.

Notice to US investors
The Voluntary Tender Offer has been made for securities of a Dutch company and holders of the Shares that are resident in the United States should be aware that this announcement and any other documents relating to the Voluntary Tender Offer have been or will be prepared in accordance with the European Union disclosure requirements, format and style, all of which differ from those in the United States. All financial information that is included in this announcement or that may be included in any documents relating to the Voluntary Tender Offer have been or will be prepared in accordance with the European Union's generally accepted accounting principles and International Financial Reporting Standards and may not be comparable to financial statements of US companies.

It may be difficult for holders of the Shares to enforce certain rights and claims arising in connection with the Voluntary Tender Offer under US federal securities laws since dsm-firmenich and DSM are located outside the United States, and their officers and most of their directors reside outside the United States. Therefore, investors may have difficulty effecting service of process within the United States upon those persons or recovering against dsm-firmenich, DSM or their respective officers or directors on judgments of US courts, including judgments based upon the civil liability provisions of the US federal securities laws. It may not be possible to sue a non-US company or its officers or directors in a non-US court for violations of US securities laws. It also may not be possible to compel a non-US company or its affiliates to subject themselves to a US court's judgment.

The Voluntary Tender Offer has been made in the United States pursuant to applicable US tender offer rules and securities laws (or pursuant to exemptive relief therefrom granted by the United States Securities and Exchange Commission). Accordingly, the Voluntary Tender Offer will be subject to disclosure and other procedural requirements, including with respect to terms, conditions and procedures that are different from those applicable under US domestic tender offer procedures and law.

Holders of the Shares that are resident in the United States also should be aware that the Voluntary Tender Offer may be a taxable transaction for US federal income tax purposes and under applicable US state and local, as well as foreign and other, tax laws and, that such consequences, if any, are not described herein. Holders of the Shares that are resident in the United States are urged to consult with legal, tax and financial advisers in connection with making a decision regarding the Voluntary Tender Offer.

Logo - https://mma.prnewswire.com/media/2071772/dsm_firmenich_Logo.jpg 


These press releases may also interest you

at 01:00
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears path for launch of Jubbonti® and Wyost® on...

at 00:30
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology...

at 00:00
The Riverside Company, a global private investor focused on the smaller end of the middle market, has closed the acquisition of Arbeidsmiljř og Energiteknikk AS (AET), a Norwegian distributor of third-party consumables and laboratory / cleaning...

at 00:00
COEUS Solutions, a leading provider of innovative technologies and services in the life sciences industry, today announces its rebranding to BridgeView Life Sciences ("BridgeView") following a recent spinoff from its former parent company. This marks...

29 avr 2024
General Inception announces the launch of Igniter Europe, focused on building innovative companies in the field of oncology, autoimmune and rare diseases, with novel therapeutics and disruptive...

29 avr 2024
The Company demonstrated a deep commitment to achieving ESG success in partnership with global clients, creating long-term value for all stakeholders.The Company made remarkable progress in tackling climate change, achieving a 29% intensity reduction...



News published on and distributed by: